Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

/ / Published in
[featured_image]
haematol.2020.275958
  • Version 1
  • Download 37
  • File Size 1.71 MB
  • File Count 1
  • Create Date September 9, 2021
  • Last Updated September 9, 2021

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Attached Files

FileAction
2020.275958.DUELL new.pdfDownload